(Q36817132)

16 August 2017

1 reference

title

Novel inhibitors in the treatment of metastatic melanoma (English)

1 reference

16 August 2017

1 reference

Kevin Kalinsky

1 reference

16 August 2017

Frank G Haluska

series ordinal

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

715-724

1 reference

Chemotherapy for metastatic melanoma: time for a change?

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

BRAF alterations are associated with complex mutational profiles in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Phosphatidylinositol 3' kinase: one of the effectors of Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Imatinib mesylate in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Imatinib mesylate for melanoma: will a new target be revealed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.715

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.715

1 reference

16 August 2017

1 reference